Wei Mo
Fudan University
20 Papers
114 Citations
Wei Mo is an academic researcher from Fudan University. The author has contributed to research in topics: Thrombin & Chemistry. The author has an hindex of 10, co-authored 20 publications. Previous affiliations of Wei Mo include Sichuan University.
Chat about Author
Papers
Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
Bing Zhao,Mengfang Wu,Zhihuang Hu,Yixin Ma,Wang Qi,Yanling Zhang,Yaran Li,Min Yu,Huijie Wang,Wei Mo,Wei Mo +10 more
TL;DR: This research revealed that thrombin induced VM formation via PAR-1-mediated NF-κB signaling cascades and illustrated that VM might be a target of r-hirudin and DTIP to suppress tumor progression.
Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor-2.
TL;DR: This study provides a method to produce hTFPI-2/KD1 efficiently and some insights into the structure and function of hT FPI- 2/K D1.
34
Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors
Xingxing Yuan,Zujun Sun,Zujun Sun,Qingyun Yuan,Weihua Hou,Qiaoyan Liang,Yuxiong Wang,Wei Mo,Huijie Wang,Min Yu +9 more
TL;DR: It is confirmed that the novel dual-function CAR-T cells exhibit stronger anti-tumor activity against solid tumors than traditional single-target CAR-t cells and present a new approach that enhance the activity of CAR- T cells in solid tumors.
27
Rehmannia inhibits adipocyte differentiation and adipogenesis.
Lin Jiang,Nai xian Zhang,Wei Mo,Rui Wan,Chun Gu Ma,Xi Li,Yin liang Gu,Xin Ying Yang,Qi Qun Tang,Hou Yan Song +9 more
TL;DR: The results indicate that Rehmannia glutinosa extract inhibits preadipocyte differentiation and adipogenesis in cultured cells and in rodent models of obesity.
26
Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities.
TL;DR: RGD-SAK possessed the bifunction to target Platelet-rich clots and to block platelets aggregation, and thus may serve as a more potential thrombolytic agent with platelet-targeted throm bolytic and antiplatelet aggregation activities in compared with SAK.